Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Niraparib & Ovarian cancer (BRCA m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

FDA status

In the context of Niraparib & Ovarian cancer (BRCA m), there is FDA approval for niraparib in Ovarian cancer (BRCA m), both in germline BRCA‑mutated recurrent disease (maintenance) and in HRD‑positive advanced disease (including BRCAm) after multiple prior lines (1, 2).

EMA status

The European Medicines Agency (EMA) has approved niraparib as:

First‑line maintenance monotherapy for adult women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum‑based chemotherapy, regardless of [BRC…

References (Sources)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
Maiorano et al. 2023 Pharmaceuticals (Basel) 16(9): 1261
Review
Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review
Gonzalez et al. 2024 Int J Womens Health 16: 2239-2246
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!